Apogee Therapeutics (NASDAQ:APGE) Trading Down 3 2% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing.
ARM: Everything You Need To Know About The Lock-Up Expiry (Rating Upgrade) (NASDAQ:ARM) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Apogee Therapeutics (NASDAQ:APGE – Free Report) had its price target hoisted by Stifel Nicolaus from $46.00 to $95.00 in a research report report published on Tuesday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock. Other equities research analysts have also recently issued reports about the company. BTIG Research started coverage […]